Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
2.

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis.

Iannello A, Rolla S, Maglione A, Ferrero G, Bardina V, Inaudi I, De Mercanti S, Novelli F, D'Antuono L, Cardaropoli S, Todros T, Turrini MV, Cordioli C, Puorro G, Marsili A, Lanzillo R, Brescia Morra V, Cordero F, De Bortoli M, Durelli L, Visconti A, Cutrupi S, Clerico M.

Front Immunol. 2019 Jan 8;9:3075. doi: 10.3389/fimmu.2018.03075. eCollection 2018.

3.

Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, Cocco E, Annovazzi P, Vladic A, Novelli F, Durelli L, Clerico M.

J Neuroimmunol. 2017 Dec 15;313:89-91. doi: 10.1016/j.jneuroim.2017.10.009. Epub 2017 Oct 17.

4.

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.

Expert Opin Drug Saf. 2017 Aug;16(8):963-972. doi: 10.1080/14740338.2017.1346082. Epub 2017 Jul 5. Review.

PMID:
28641055
5.

Natalizumab in Multiple Sclerosis: Long-Term Management.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L.

Int J Mol Sci. 2017 Apr 29;18(5). pii: E940. doi: 10.3390/ijms18050940. Review.

6.

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.

Clerico M, De Mercanti S, Artusi CA, Durelli L, Naismith RT.

Mult Scler. 2017 May;23(6):874-876. doi: 10.1177/1352458516688350. Epub 2017 Feb 1.

PMID:
28290755
7.

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea.

Barbero P, Busso M, Artusi CA, De Mercanti S, Tinivella M, Veltri A, Durelli L, Clerico M.

J Vis Exp. 2016 Nov 9;(117). doi: 10.3791/54606.

8.

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2016 Aug;3(4):e273.

9.

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

Barbero P, Busso M, Tinivella M, Artusi CA, De Mercanti S, Cucci A, Veltri A, Avagnina P, Calvo A, Chio' A, Durelli L, Clerico M.

J Neurol. 2015 Dec;262(12):2662-7. doi: 10.1007/s00415-015-7894-1. Epub 2015 Sep 26.

PMID:
26410746
10.

Epigenetic therapy for Friedreich ataxia.

Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O'Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR.

Ann Neurol. 2014 Oct;76(4):489-508. doi: 10.1002/ana.24260. Epub 2014 Sep 16.

11.

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.

Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M.

J Leukoc Biol. 2014 Dec;96(6):1155-64. doi: 10.1189/jlb.5A0813-463RR. Epub 2014 Aug 5.

PMID:
25097195
12.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.

JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.

PMID:
24977406
13.

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, Halper J, Harris C, Herbert J, Li D, Lincoln JA, Lisak R, Lublin FD, Lucchinetti CF, Moore W, Naismith RT, Oehninger C, Simon J, Sormani MP.

Int J MS Care. 2012 Fall;14(3):105-14. doi: 10.7224/1537-2073-14.3.105.

14.

Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2.

Conti L, De Palma R, Rolla S, Boselli D, Rodolico G, Kaur S, Silvennoinen O, Niccolai E, Amedei A, Ivaldi F, Clerico M, Contessa G, Uccelli A, Durelli L, Novelli F.

J Immunol. 2012 Feb 1;188(3):1011-8. doi: 10.4049/jimmunol.1004013. Epub 2012 Jan 4.

15.

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.

Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, Trojano M, Gallo P, Capra R, Centonze D, Millefiorini E, Sotgiu S, Brescia Morra V, Amato MP, Lugaresi A, Mancardi G, Caputo D, Montanari E, Provinciali L, Durelli L, Bergamaschi R, Bellantonio P, Tola MR, Cottone S, Savettieri G, Tedeschi G; MS-SIN Study Group.

Neurol Sci. 2011 Apr;32(2):351-8. doi: 10.1007/s10072-010-0469-0.

PMID:
21234775
16.

Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.

Cucci A, Barbero P, Clerico M, Ferrero B, Versino E, Contessa G, Demercanti S, Viglietta E, Di Liberto A, Vai AG, Durelli L.

J Neuroimmunol. 2010 Sep 14;226(1-2):150-7. doi: 10.1016/j.jneuroim.2010.05.038. Epub 2010 Jun 23.

PMID:
20573405
17.

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F.

Ann Neurol. 2009 May;65(5):499-509. doi: 10.1002/ana.21652.

PMID:
19475668
18.

Risk factors for tumor occurrence in patients with myasthenia gravis.

Citterio A, Beghi E, Millul A, Evoli A, Mantegazza R, Antozzi C, Baggi F, Cornelio F, Durelli L, Clerico M, Piccolo G, Cosi V.

J Neurol. 2009 Aug;256(8):1221-7. doi: 10.1007/s00415-009-5091-9. Epub 2009 Mar 29.

PMID:
19330280
19.

Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.

Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group.

Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781 .

PMID:
19278300
20.

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.

Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group.

J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25.

PMID:
18825438
21.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005278. doi: 10.1002/14651858.CD005278.pub3. Review.

PMID:
18425915
22.

The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.

Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L.

Clin Neurol Neurosurg. 2008 Nov;110(9):878-85. doi: 10.1016/j.clineuro.2007.10.020. Epub 2008 Mar 4. Review.

PMID:
18164542
23.

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis.

Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Rivoiro C, Ferrero C, Picco E, Ripellino P, Giuliani G, Montanari E, Clerico M; Italian Multiple Sclerosis Study Group.

J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):646-51. Epub 2007 Nov 6.

PMID:
17986500
24.

Adherence to interferon-beta treatment and results of therapy switching.

Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L.

J Neurol Sci. 2007 Aug 15;259(1-2):104-8. Epub 2007 Mar 21. Review.

PMID:
17376486
25.

Interferon-beta1a for the treatment of multiple sclerosis.

Clerico M, Contessa G, Durelli L.

Expert Opin Biol Ther. 2007 Apr;7(4):535-42. Review.

PMID:
17373904
26.

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

Durelli L, Barbero P, Clerico M; INCOMIN Trial Study Group.

Neurology. 2006 Dec 26;67(12):2264; author reply 2264-5. No abstract available.

PMID:
17190964
27.

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.

Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L; INCOMIN Trial Study Group.

Mult Scler. 2006 Feb;12(1):72-6. Erratum in: Mult Scler. 2006 Dec;12(6):830.

PMID:
16459722
28.

Comparison of immunomodulatory treatments for multiple sclerosis.

Durelli L, Clerico M.

Eur J Neurol. 2005 Nov;12(11):915; author reply 916. No abstract available.

PMID:
16241984
29.

The importance of maintaining effective therapy in multiple sclerosis.

Durelli L, Clerico M.

J Neurol. 2005 Sep;252 Suppl 3:iii38-iii43. Review.

PMID:
16170500
30.

Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells.

Isoardo G, Deaglio S, Cocito D, Migliaretti G, Ferrero E, Cavallo F, Durelli L, Malavasi F.

J Neuroimmunol. 2005 Apr;161(1-2):78-86.

PMID:
15748946
31.

Is multiple sclerosis a disease that requires frequent beta interferon dosing?

Durelli L.

J Neurol. 2004 Sep;251 Suppl 4:IV13-24. Review.

PMID:
15378303
32.
33.

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.

Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.

J Neurol Sci. 2004 Jul 15;222(1-2):13-9.

PMID:
15240190
34.

Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features.

Isoardo G, Bergui M, Durelli L, Barbero P, Boccadoro M, Bertola A, Ciaramitaro P, Palumbo A, Bergamasco B, Cocito D.

Acta Neurol Scand. 2004 Mar;109(3):188-93.

PMID:
14763956
35.

Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.

Durelli L.

J Neurol. 2003 Dec;250 Suppl 4:IV9-IV14. Review.

PMID:
14712396
36.

Immunoglobulin treatment of multiple sclerosis: future prospects.

Durelli L, Ricci A, Verdun E.

Neurol Sci. 2003 Oct;24 Suppl 4:S234-8. Review.

PMID:
14598050
37.

Different clinical, electrophysiological and immunological features of CIDP associated with paraproteinaemia.

Cocito D, Durelli L, Isoardo G.

Acta Neurol Scand. 2003 Oct;108(4):274-80. Review.

PMID:
12956862
38.

Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118.

Durelli L, Verdun E, Barbero P, Bergui M, Versino E; INCOMIN Trial Study Group.

Clin Ther. 2003 Jun;25(6):1890-3. No abstract available.

PMID:
12868445
39.

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR, Hartung HP, Durelli L, Edan G, Fernández O, Seeldrayers P, Sørensen P, Margrie S, Rovaris M, Comi G, Filippi M; Early Treatment of Multiple Sclerosis Study Group.

Ann Neurol. 2003 Jun;53(6):718-24.

PMID:
12783417
40.

Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP.

Cocito D, Ciaramitaro P, Isoardo G, Barbero P, Migliaretti G, Pipieri A, Proto G, Quadri R, Bergamasco B, Durelli L.

J Neurol. 2002 Jun;249(6):719-22.

PMID:
12111305
41.

High-dose intravenous immunoglobulin treatment of multiple sclerosis.

Durelli L, Isoardo G.

Neurol Sci. 2002 Apr;23 Suppl 1:S39-48. Review.

PMID:
12032586
42.

High-dose intravenous immunoglobulin G treatment of myasthenia gravis.

Ferrero B, Durelli L.

Neurol Sci. 2002 Apr;23 Suppl 1:S9-24. Review.

PMID:
12032583
43.

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M; Independent Comparison of Interferon (INCOMIN) Trial Study Group.

Lancet. 2002 Apr 27;359(9316):1453-60.

PMID:
11988242
44.

Hypothalamic-pituitary-adrenal axis function and cytokine production in multiple sclerosis with or without interferon-beta treatment.

Limone P, Ferrero B, Calvelli P, Del Rizzo P, Rota E, Berardi C, Barberis AM, Isaia GC, Durelli L.

Acta Neurol Scand. 2002 May;105(5):372-7.

PMID:
11982488
45.

Effects of high doses of corticosteroids on bone metabolism.

Ardissone P, Rota E, Durelli L, Limone P, Isaia GC.

J Endocrinol Invest. 2002 Feb;25(2):129-33.

PMID:
11929083
46.

Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?

Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, Montanari E, Zaffaroni M, Durelli L; Betaferon Safety Trial (BEST) Study Group.

J Interferon Cytokine Res. 2002 Feb;22(2):245-55. Erratum in: J Interferon Cytokine Res 2002 Apr;22(4):504.

PMID:
11911808
47.

Diffusion-weighted MR in reversible wernicke encephalopathy.

Bergui M, Bradac GB, Zhong JJ, Barbero PA, Durelli L.

Neuroradiology. 2001 Nov;43(11):969-72.

PMID:
11760803
48.

Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study.

Durelli L, Oggero A, Verdun E, Isoardo GL, Barbero P, Bergamasco B, Brossa PC, Ghigo E, Maccario M, Faggiano F; Betaferon Safety Trial (BEST) Study Group.

J Neurol Sci. 2001 Dec 15;193(1):17-22.

PMID:
11718745
49.

Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.

Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M; Betaferon Safety Trial (BEST) Study Group.

Neurology. 2001 Oct 23;57(8):1363-70.

PMID:
11673572
50.

Interferon-beta dose and efficacy: the OPTIMS study.

Durelli L, Oggero A, Verdun E, Barbero P, Pipieri A, Isoardo G, Ricci A, Clerico M, Bradac G, Bergamasco B, Bergui M.

Neurol Sci. 2001 Apr;22(2):201-3.

PMID:
11603627

Supplemental Content

Loading ...
Support Center